Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Correlations between dual-phase 18F-FDG uptake and clinicopathologic and biological markers of breast cancer.

Kaida H, Azuma K, Toh U, Kawahara A, Sadashima E, Hattori S, Akiba J, Tahara N, Rominger A, Ishii K, Murakami T, Ishibashi M.

Hell J Nucl Med. 2018 Jan-Apr;21(1):35-42. doi: 10.1967/s002449910705. Epub 2018 Mar 20.

2.

Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.

Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Katayama K, Koga T, Kurashita K, Hasegawa S, Todoroki H, Kai Y, Ohi Y, Toyoshima S, Arima N, Mitsuyama S, Tamura K.

Oncology. 2017;93(1):51-61. doi: 10.1159/000468521. Epub 2017 May 6.

PMID:
28478451
3.

Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.

Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Naitou M, Sasada T, Hattori N, Kohno N, Itoh K.

Cancer Sci. 2017 Apr;108(4):598-603. doi: 10.1111/cas.13189. Epub 2017 Apr 21.

4.

Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.

Shibata T, Watari K, Izumi H, Kawahara A, Hattori S, Fukumitsu C, Murakami Y, Takahashi R, Toh U, Ito KI, Ohdo S, Tanaka M, Kage M, Kuwano M, Ono M.

Cancer Res. 2017 Jan 15;77(2):545-556. doi: 10.1158/0008-5472.CAN-16-1593. Epub 2016 Nov 22.

5.

Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.

Okabe M, Toh U, Iwakuma N, Saku S, Akashi M, Kimitsuki Y, Seki N, Kawahara A, Ogo E, Itoh K, Akagi Y.

Cancer Sci. 2017 Jan;108(1):81-90. doi: 10.1111/cas.13114. Epub 2017 Jan 21.

6.

[Development of Peptide Vaccines for Triple-Negative Breast Cancer Treatment].

Toh U, Saku S, Okabe M, Iwakuma N, Kimitsuki Y, Akashi M, Ogo E, Yamada A, Shichijo S, Itoh K, Akagi Y.

Gan To Kagaku Ryoho. 2016 Oct;43(10):1249-1251. Japanese.

PMID:
27760950
7.

[Pretreatment and Posttreatment Evaluations of Circulating Tumor Cells(CTC)in Patients with Metastatic Breast Cancer].

Okabe M, Toh U, Iwakuma N, Mishima M, Matsueda S, Shichijo S, Itoh K, Akagi Y.

Gan To Kagaku Ryoho. 2015 Oct;42(10):1237-9. Japanese.

PMID:
26489558
8.

Navigation surgery for intraoperative sentinel lymph node detection using Indocyanine green (ICG) fluorescence real-time imaging in breast cancer.

Toh U, Iwakuma N, Mishima M, Okabe M, Nakagawa S, Akagi Y.

Breast Cancer Res Treat. 2015 Sep;153(2):337-44. doi: 10.1007/s10549-015-3542-9. Epub 2015 Aug 13.

PMID:
26267663
9.

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.

Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Sasada T, Hattori N, Kohno N, Itoh K.

Cancer Sci. 2015 Oct;106(10):1257-63. doi: 10.1111/cas.12757. Epub 2015 Sep 25.

10.

Evaluation of contrast Sonazoid-enhanced ultrasonography for the detection of hepatic metastases in breast cancer.

Mishima M, Toh U, Iwakuma N, Takenaka M, Furukawa M, Akagi Y.

Breast Cancer. 2016 Mar;23(2):231-41. doi: 10.1007/s12282-014-0560-0. Epub 2014 Aug 21.

11.

Observational study of axilla treatment for breast cancer patients with 1-3 positive micrometastases or macrometastases in sentinel lymph nodes.

Oba MS, Imoto S, Toh U, Wada N, Kawada M, Kitada M, Masuda N, Taguchi T, Minami S, Jinno H, Sakamoto J, Morita S; Japanese Society for Sentinel Node Navigation Surgery.

Jpn J Clin Oncol. 2014 Sep;44(9):876-9. doi: 10.1093/jjco/hyu090. Epub 2014 Jul 16.

PMID:
25030214
12.

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.

Takahashi R, Toh U, Iwakuma N, Takenaka M, Otsuka H, Furukawa M, Fujii T, Seki N, Kawahara A, Kage M, Matsueda S, Akagi Y, Yamada A, Itoh K, Sasada T.

Breast Cancer Res. 2014 Jul 3;16(4):R70. doi: 10.1186/bcr3685.

13.

FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis.

Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T, Koura K, Takahashi R, Otsuka H, Takahashi H, Iwakuma N, Nakagawa S, Fujii T, Sasada T, Yamaguchi R, Yano H, Shirouzu K, Kage M.

Mol Clin Oncol. 2013 Jul;1(4):625-632. Epub 2013 Apr 26.

14.

Primary breast peripheral T-cell lymphoma not otherwise specified: report of a case.

Muroya D, Toh U, Iwakuma N, Nakagawa S, Mishima M, Takahashi R, Takenaka M, Shirouzu K, Agaki Y.

Surg Today. 2015 Jan;45(1):115-20. doi: 10.1007/s00595-013-0808-x. Epub 2014 Jan 7.

15.

Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy.

Takahashi R, Toh U, Iwakuma N, Mishima M, Fujii T, Takenaka M, Koura K, Seki N, Kawahara A, Kage M, Ogo E, Shirouzu K.

Exp Ther Med. 2013 Nov;6(5):1089-1095. Epub 2013 Sep 6.

16.

Usefulness of endoscopic breast-conserving surgery for breast cancer.

Takahashi H, Fujii T, Nakagawa S, Inoue Y, Akashi M, Toh U, Iwakuma N, Takahashi R, Takenaka M, Fukuma E, Shirouzu K.

Surg Today. 2014 Nov;44(11):2037-44. doi: 10.1007/s00595-013-0767-2. Epub 2013 Oct 24.

PMID:
24150099
17.

Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.

Otsuka H, Fujii T, Toh U, Iwakuma N, Takahashi R, Mishima M, Takenaka M, Kakuma T, Tanaka M, Shirouzu K.

Breast Cancer. 2015 Jul;22(4):335-42. doi: 10.1007/s12282-013-0483-1. Epub 2013 Jul 5.

PMID:
23827973
18.

The relationship between 18F-FDG metabolic volumetric parameters and clinicopathological factors of breast cancer.

Kaida H, Toh U, Hayakawa M, Hattori S, Fujii T, Kurata S, Kawahara A, Hirose Y, Kage M, Ishibashi M.

Nucl Med Commun. 2013 Jun;34(6):562-70. doi: 10.1097/MNM.0b013e328360d945.

PMID:
23619341
19.

Detection of Demodex folliculorum from nipple discharge.

Yokoyama T, Yamaguchi R, Itoh T, Toh U, Nakagawa S, Kage M.

Diagn Cytopathol. 2014 Mar;42(3):236-7. doi: 10.1002/dc.22952. Epub 2013 Feb 26. No abstract available.

PMID:
23440967
20.

Tricin inhibits proliferation of human hepatic stellate cells in vitro by blocking tyrosine phosphorylation of PDGF receptor and its signaling pathways.

Seki N, Toh U, Kawaguchi K, Ninomiya M, Koketsu M, Watanabe K, Aoki M, Fujii T, Nakamura A, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H.

J Cell Biochem. 2012 Jul;113(7):2346-55. doi: 10.1002/jcb.24107.

PMID:
22359269
21.

Giant malignant phyllodes tumor: a case report.

Takenaka M, Toh U, Otsuka H, Takahashi H, Iwakuma N, Nakagawa S, Fujii T, Yamaguchi R, Yano H, Shirouzu K, Kage M.

Kurume Med J. 2011;58(2):67-72.

22.

Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination.

Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K.

Cancer Biol Ther. 2010 Dec 15;10(12):1266-79. Epub 2010 Dec 15.

PMID:
20935522
23.

[A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy].

Takahashi H, Fujii T, Inoue Y, Katsura M, Yokoyama G, Matsubayashi Namoto R, Nakayama Y, Momosaki S, Ariyama H, Takenaka M, Otsuka H, Iwakuma N, Toh U, Shirouzu K.

Gan To Kagaku Ryoho. 2010 Aug;37(8):1607-9. Japanese.

PMID:
20716898
24.

Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.

Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H.

Mol Cancer Ther. 2010 Jun;9(6):1842-51. doi: 10.1158/1535-7163.MCT-09-0918. Epub 2010 Jun 1.

25.

Clinicocytopathology of breast cancers with a ring-like appearance on ultrasonography and/or magnetic resonance imaging.

Yamaguchi R, Tanaka M, Yokoyama T, Nonaka Y, Kojima K, Terasaki H, Yamaguchi M, Fukunaga M, Toh U, Nakashima O, Kage M, Yano H.

Pathol Int. 2010 Jan;60(1):22-6. doi: 10.1111/j.1440-1827.2009.02471.x. Erratum in: Pathol Int. 2010 Apr;60(4):336. Nonaka, Hideyuki [corrected to Nonaka, Yasuhide].

PMID:
20055948
26.

[A case of triple negative chest wall recurrent breast cancer treated with capecitabine and docetaxel combination therapy (XT therapy)].

Sawada Y, Fujii T, Takahashi H, Yokoyama G, Matsubayashi RN, Inoue Y, Uesugi N, Momosaki S, Toh U, Shirouzu K.

Gan To Kagaku Ryoho. 2009 May;36(5):815-7. Japanese.

PMID:
19461184
27.

YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cells.

Fujii T, Seki N, Namoto-Matsubayashi R, Takahashi H, Inoue Y, Toh U, Kage M, Shirouzu K.

Future Oncol. 2009 Mar;5(2):153-6. doi: 10.2217/14796694.5.2.153.

PMID:
19284373
28.
29.

Adenomyoepithelioma of the breast diagnosed by a mammotome biopsy: report of a case.

Yahara T, Yamaguchi R, Yokoyama G, Yamaguchi M, Nakagawa S, Toh U, Shirouzu K, Kage M, Fujii T.

Surg Today. 2008;38(2):144-6. doi: 10.1007/s00595-007-3591-8. Epub 2008 Feb 1.

PMID:
18239872
30.

Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer.

Fujii T, Yokoyama G, Takahashi H, Namoto R, Nakagawa S, Toh U, Kage M, Shirouzu K, Kuwano M.

Breast Cancer. 2008;15(1):73-8. doi: 10.1007/s12282-007-0015-y.

PMID:
18224398
31.

[Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer].

Toh U, Fujii T, Mishima M, Imaizumi T, Koga A, Yano S, Shirouzu K, Yahara T, Yamana H.

Gan To Kagaku Ryoho. 2007 Nov;34(12):1931-3. Japanese.

PMID:
18219856
32.

[Usefulness of 18F-FDG-PET in breast cancer imaging].

Tayama K, Toh U, Fujii T, Shirouzu K, Kaida Y.

Nihon Rinsho. 2007 Jun 28;65 Suppl 6:373-8. Review. Japanese. No abstract available.

PMID:
17679209
33.

The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.

Brooks AD, Ramirez T, Toh U, Onksen J, Elliott PJ, Murphy WJ, Sayers TJ.

Ann N Y Acad Sci. 2005 Nov;1059:160-7.

PMID:
16382051
34.

Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion.

Toh U, Fujii T, Seki N, Niiya F, Shirouzu K, Yamana H.

Cancer Immunol Immunother. 2006 Oct;55(10):1219-27. Epub 2005 Dec 16.

PMID:
16362409
35.

[Combination immunotherapy using autologous tumor-stimulated lymphocytes and trastuzumab (Herceptin) for the patients with recurrent breast cancer].

Toh U, Fujii T, Miwa K, Yokoyama G, Yamaguchi M, Kawamura D, Machida E, Shirouzu K, Yamana H.

Gan To Kagaku Ryoho. 2005 Oct;32(11):1789-91. Japanese.

PMID:
16315942
36.

Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells.

Fujii T, Nakamura AM, Yokoyama G, Yamaguchi M, Tayama K, Miwa K, Toh U, Kawamura D, Shirouzu K, Yamana H, Kuwano M, Tsuda H.

Oncol Rep. 2005 Aug;14(2):489-94.

PMID:
16012735
37.

Advanced chemoresistant breast cancer responding to multidisciplinary treatment with hyperthermia, radiotherapy, and intraarterial infusion.

Yokoyama G, Fujii T, Ogo E, Yanaga H, Toh U, Yamaguchi M, Mishima M, Takamori S, Shirouzu K, Yamana H.

Int J Clin Oncol. 2005 Apr;10(2):139-43.

PMID:
15864701
38.

[Intra-arterial cellular immunochemotherapy for unresectable pancreatic cancer with liver metastasis].

Horiuchi H, Toh U, Uchida S, Hayashi K, Kinoshita H, Yamana H, Aoyagi S, Shirouzu K, Koganemaru M.

Gan To Kagaku Ryoho. 2004 Oct;31(11):1752-4. Japanese.

PMID:
15553704
39.

[The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].

Toh U, Fujii T, Tayama K, Yanaga H, Yokoyama G, Yamaguchi M, Horiuchi H, Sasatomi T, Takamori S, Shirouzu K, Seki N, Yamana H.

Gan To Kagaku Ryoho. 2004 Oct;31(11):1649-51. Japanese.

PMID:
15553672
40.

[Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].

Toh U, Yamana H, Kido K, Mine T, Fujii T, Horiuchi H, Sasatomi T, Ishibashi N, Yutani S, Fujita H, Shirouzu K.

Gan To Kagaku Ryoho. 2003 Oct;30(11):1566-70. Japanese.

PMID:
14619465
41.

Histopathological analysis of non-malignant and malignant epithelium in achalasia of the esophagus.

Fujii T, Yamana H, Sueyoshi S, Fujita H, Tanaka Y, Kubota M, Toh U, Mine T, Sasahara H, Shirouzu K, Kato S, Morimatsu M.

Dis Esophagus. 2000;13(2):110-6.

PMID:
14601900
42.

Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study.

Heroor A, Fujita H, Sueyoshi S, Tanaka T, Toh U, Mine T, Sasahara H, Sudo T, Matono S, Yamana H, Shirouzu K.

Dig Surg. 2003;20(3):229-35; discussion 236-7.

PMID:
12759503
43.

Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy.

Fujita H, Sueyoshi S, Tanaka T, Fujii T, Toh U, Mine T, Sasahara H, Sudo T, Matono S, Yamana H, Shirouzu K.

World J Surg. 2003 May;27(5):571-9. Epub 2003 Apr 28.

PMID:
12715226
44.

Locoregional adoptive immunotherapy resulted in regression in distant metastases of a recurrent esophageal cancer.

Toh U, Sudo T, Kido K, Matono S, Sasahara H, Mine T, Tanaka T, Sueyoshi S, Fujita H, Shirouzu K, Yamana H.

Int J Clin Oncol. 2002 Dec;7(6):372-5.

PMID:
12494255
45.

Intraarterial cellular immunotherapy for patients with inoperable liver metastases of esophageal cancer.

Toh U, Sudo T, Kido K, Tanaka T, Sueyoshi S, Fujita H, Hiraki M, Horiuchi H, Shirouzu K, Yamana H.

Gan To Kagaku Ryoho. 2002 Nov;29(12):2152-6.

PMID:
12484026
46.

[Cellular immunotherapy for local recurrence of rectal cancer after surgery by activated lymphocyte administration--a case report].

Sasatomi T, Toh U, Miyagi Y, Ishibashi N, Araki Y, Ogata Y, Yamana H, Shirouzu K.

Gan To Kagaku Ryoho. 2001 Oct;28(11):1692-5. Japanese.

PMID:
11708011
47.

[Cancer vaccine with peptides derived from tumor rejection antigens].

Niiya F, Mine T, Toh U, Yamana H, Itoh K.

Nihon Rinsho. 2001 Apr;59 Suppl 4:438-42. Review. Japanese. No abstract available.

PMID:
11424421
48.

Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy.

Fujita H, Sueyoshi S, Yamana H, Shinozaki K, Toh U, Tanaka Y, Mine T, Kubota M, Shirouzu K, Toyonaga A, Harada H, Ban S, Watanabe M, Toda Y, Tabuchi E, Hayabuchi N, Inutsuka H.

World J Surg. 2001 Apr;25(4):424-31.

PMID:
11344392
49.

Locoregional cellular immunotherapy for patients with advanced esophageal cancer.

Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K, Itoh K.

Clin Cancer Res. 2000 Dec;6(12):4663-73.

50.

Radical esophagectomy and secondary anastomosis for high-risk patients with intrathoracic esophageal carcinoma.

Sueyoshi S, Yamana H, Fujita H, Tanaka T, Toh U, Kubota M, Tanaka Y, Mine T, Sasahara H, Shirouzu K.

Jpn J Thorac Cardiovasc Surg. 2000 Nov;48(11):683-7.

PMID:
11144085

Supplemental Content

Support Center